摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-二氯-N-(4-氯苯基)-2-羟基苯甲酰胺 | 1151-51-5

中文名称
3,5-二氯-N-(4-氯苯基)-2-羟基苯甲酰胺
中文别名
——
英文名称
3,5-dichloro-N-(4-chlorophenyl)-2-hydroxybenzamide
英文别名
3,5-dichloro-2-hydroxy-benzoic acid-(4-chloro-anilide);3,5-Dichlor-2-hydroxy-benzoesaeure-(4-chlor-anilid);3,4',5-trichlorosalicylanilide;3,4'5-trichloro-salicylanilide;Benzamide, 3,5-dichloro-N-(4-chlorophenyl)-2-hydroxy-
3,5-二氯-N-(4-氯苯基)-2-羟基苯甲酰胺化学式
CAS
1151-51-5
化学式
C13H8Cl3NO2
mdl
MFCD00437181
分子量
316.571
InChiKey
USFZGCVGLNMJPL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    142.5 °C
  • 沸点:
    383.7±42.0 °C(Predicted)
  • 密度:
    1.562±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    49.3
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:3554bc97682da6633acd081899b1d15d
查看

反应信息

  • 作为反应物:
    描述:
    3,5-二氯-N-(4-氯苯基)-2-羟基苯甲酰胺亚磷酸二乙酯三乙胺 作用下, 以 四氯化碳氯仿 为溶剂, 反应 6.0h, 以58.1%的产率得到[2,4-dichloro-6-[(4-chlorophenyl)carbamoyl]phenyl] diethyl phosphate
    参考文献:
    名称:
    Kryukov, L. N.; Lebedeva, N. Yu.; Kostrova, S. M., Journal of general chemistry of the USSR, 1990, vol. 60, # 5, p. 941 - 944
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    Design, Synthesis, and Biological Activities of Closantel Analogues: Structural Promiscuity and Its Impact on Onchocerca volvulus
    摘要:
    Onchocerciasis, or river blindness, is a neglected tropical disease that affects more than 37 million people worldwide, primarily in Africa and Central and South America. We have disclosed evidence that the larval-stage-specific chitinase, OvCHT1, may be a potential biological target for affecting nematode development. On the basis of screening efforts, closantel, a known anthelmintic drug, was discovered as a potent and highly specific OvCHT1 inhibitor. Originally, closantel's anthelmintic mode of action was believed to rely solely on its role as a proton ionophore; thus, the impact of each of its biological activities on O. volvulus L3 molting was investigated. Structure activity relationship studies on an active closantel fragment are detailed, and remarkably, by use of a simple salicylanilide scaffold, compounds acting only as protonophores or chitinase inhibitors were identified. From these data, unexpected synergistic protonophore and chitinase inhibition activities have also been found to be critical for molting in O. volvulus L3 larvae.
    DOI:
    10.1021/jm200364n
点击查看最新优质反应信息

文献信息

  • Relationships Between the Chemical Structure of Antimycobacterial Substances and Their Activity Against Atypical Strains. Part 14: 3-Aryl-6,8-dihalogeno-2H-1,3-benzoxazine-2,4(3H)-diones
    作者:Karel Waisser、Jana Hladuvková、Jirí Gregor、Tomáš Rada、Lenka Kubicová、Vera Klimešová、Jarmila Kaustová
    DOI:10.1002/(sici)1521-4184(199801)331:1<3::aid-ardp3>3.0.co;2-2
    日期:1998.1
    6,8‐dibromo‐3‐phenyl‐2H‐1,3‐benzoxazine‐2,4(3H)‐dione, substituted on the phenyl ring, was prepared by the reaction of the corresponding salicylanilides with ethyl chloroformate. The compounds were evaluated in vitro for antimycobacterial activity against Mycobacterium tuberculosis, Mycobacterium kansasii, and Mycobacterium avium. Their activity increases with increasing hydrophobicity and electron‐withdrawing
    6,8-二氯-3-苯基-2H-苯并恶嗪-2,4(3H)-二酮的八种衍生物和6,8-二溴-3-苯基-2H-1,3-苯并恶嗪-的九种衍生物苯环上取代的 2,4 (3H)-二酮是通过相应的水杨酰苯胺与氯甲酸乙酯反应制备的。在体外评估了这些化合物对结核分枝杆菌、堪萨斯分枝杆菌和鸟分枝杆菌的抗分枝杆菌活性。它们的活性随着苯环上取代基的疏水性和吸电子能力的增加而增加。
  • Substituted Salicylanilides as Inhibitors of Two-Component Regulatory Systems in Bacteria
    作者:Mark J. Macielag、James P. Demers、Stephanie A. Fraga-Spano、Dennis J. Hlasta、Sigmond G. Johnson、Ramesh M. Kanojia、Ronald K. Russell、Zhihua Sui、Michele A. Weidner-Wells、Harvey Werblood、Barbara D. Foleno、Raul M. Goldschmidt、Michael J. Loeloff、Glenda C. Webb、John F. Barrett
    DOI:10.1021/jm9803572
    日期:1998.7.1
    A new class of inhibitors of the two-component regulatory systems (TCS) of bacteria was discovered based on the salicylanilide screening hits, closantel (1) and tetrachlorosalicylanilide (9). A systematic SAR study versus a model TCS, KinA/Spo0F, demonstrated the importance of electron-attracting substituents in the salicyloyl ring and hydrophobic groups in the anilide moiety for optimal activity.
    基于水杨酰苯胺的筛选命中氯梭菌(1)和四氯水杨酰苯胺(9),发现了一种新型的细菌两组分调节系统(TCS)抑制剂。系统的SAR研究与模型TCS KinA / Spo0F相比,证明了水杨酰环中吸引电子的取代基和苯胺部分中的疏水基团具有最佳活性的重要性。另外,含有2,3-二羟基苯甲腈结构基序的衍生物8和16是KinA激酶自磷酸化的有效抑制剂,IC50分别为2.8和6. 3 µM。化合物8还以低于抑制生长的浓度抑制了基因工程化粪肠球菌细胞系中介导万古霉素抗性的TCS(VanS / VanR)。氯沙坦(1),四氯水杨基苯胺(9),
  • ACTIVE DELIVERY SYSTEMS FORMULATIONS
    申请人:HOMOLA Andrew M.
    公开号:US20100040565A1
    公开(公告)日:2010-02-18
    The present invention relates to active delivery system formulations, and methods of making and using the same. Said formulations, when applied to a substrate surface, form a protective coating on the surface and permit constituent active agents to act on the surface and in the surrounding medium.
    本发明涉及活性传递系统配方,以及制备和使用这些配方的方法。当这些配方应用到基底表面时,在表面形成一层保护性涂层,并允许组分活性剂在表面和周围介质中起作用。
  • Dentifrice compositions
    申请人:UNILEVER PLC
    公开号:EP0161898A2
    公开(公告)日:1985-11-21
    It is disclosed that a dentifrice which includes a surfactant and an anti-plaque agent comprising a substantially water--insoluble non-cationic antimicrobial agent or a zinc salt or a mixture thereof has enhanced activity when the dentifrice comprises at least 0.2% by weight of a lamellar liquid crystal surfactant phase having a lamellar spacing of less than 6.0 nm.
    据公开,当牙膏中含有至少 0.2% (按重量计)的片状液晶表面活性剂相(其片状间距小于 6.0 nm)时,牙膏的活性增强,该牙膏包括表面活性剂和抗牙菌斑剂,抗牙菌斑剂包括基本上不溶于水的非阳离子抗菌剂或锌盐或它们的混合物。
  • Cancer therapy system
    申请人:THERAPEUTICAL SYSTEMS CORPORATION
    公开号:EP0412211A1
    公开(公告)日:1991-02-13
    A method for effecting oncolysis, regression, and control of malignant neoplasms in humans and other mammals without adverse effects on normal body cells is described. An ATP-availability depressor may be combined with a defined nutritional regimen, a fatty acid blocker, an amino acid blocker, a lactate export blocker, or any combination thereof.
    本文描述了一种在不对正常体细胞产生不利影响的情况下,对人类和其他哺乳动物的恶性肿瘤进行溶解、消退和控制的方法。ATP 利用率抑制剂可与确定的营养方案、脂肪酸阻断剂、氨基酸阻断剂、乳酸输出阻断剂或它们的任何组合结合使用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐